ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2081

Harnessing the Power of Social Media for Good: Using Instagram as a Formative Assessment Tool
Abstract Number: 1295

Having More Tender Than Swollen Joints Is Associated with Worse Functional Outcomes in Patients with Early RA in a Prospective Real-World Cohort
Abstract Number: 0562

HDL-Cholesterol Efflux and the Complement System Are Linked in Systemic Lupus Erythematosus
Abstract Number: 2596

Head-To-Head Comparison of the Effectiveness of Tocilizumab, Rituximab, Mycophenolate Mofetil, and Cyclophosphamide in Patients with SSc-ILD from the EUSTAR Database
Abstract Number: 0840

Head-to-Head Comparison of TLL-018 and Tofacitinib in Patients with Active Rheumatoid Arthritis: Final Results from a Phase IIa Study
Abstract Number: 1015

Health Care Access in an Indigenous North American Population of Rheumatoid Arthritis Patients and Their At-risk First-Degree Relatives
Abstract Number: 2460

Health Care Segregation, but Not Metropolitan Area Segregation, Magnifies Racial Disparities in Hospital Outcomes of Pediatric Lupus
Abstract Number: 2351

Health Outcomes Among Patients (Pts) with SLE Initiating Belimumab (BEL) with and Without the Use of Immunosuppressants in the Previous 2 Years
Abstract Number: 2029

Health-Related Quality of Life in Idiopathic Inflammatory Myopathies: How to Act for Improving the Disease Burden of Patients?
Abstract Number: 1851

Healthcare Providers’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar
Abstract Number: 0167

Healthcare Resource Utilization Associated with Tumor-Induced Osteomalacia: Review of Patient Histories Prior to Entry in Clinical Trial UX023T-CL201
Abstract Number: 1899

Healthy People with Lupus 2030: Goals to Improve the Quality of Care and Health of All People with Lupus in the United States
Abstract Number: 1983

Heated Mittens for Patients with Hand Osteoarthritis: A Randomized Trial
Abstract Number: 0200

Herpes Zoster Prevalence in Patients with Rheumatic Diseases
Abstract Number: 0311

Heterogeneity and Natural History of Medial Fixed Joint Space Width in Healthy Knees Among Women and Men: Data from Three Large Cohort Studies

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].